Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Phase II: Randomized Neoadjuvant Treatment of Oral Cavity Cancer With Spatially Fractionated Proton Radiotherapy and Immunotherapy (OSPRI)
This phase II trial compares the effect of adding proton spatially fractionated radiotherapy (SFRT) or photon stereotactic body radiotherapy (SBRT) to standard immunotherapy pembrolizumab before surgery (neoadjuvant) in treating patients with oral cavity squamous cell cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has come back where it first started (primary site) or near it (locoregionally recurrent) and have not had (naive) prior radiation. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Proton SFRT is a type of external beam radiation treatment that uses streams of protons (tiny particles with a positive charge) to deliver different doses of radiation to different parts of the tumor in a grid like pattern. This type of radiation kills tumor cells but does not damage nearby tissues. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving neoadjuvant proton SFRT or SBRT in combination with pembrolizumab may be safe and tolerable and may be an effective approach to shrink the tumor, reduce the extent of surgery and/or the need for further treatment in patients with locally advanced or locoregionally recurrent oral cavity squamous cell cancer.
Studieöversikt
Status
Betingelser
Intervention / Behandling
- Procedur: Biospecimen Collection
- Biologisk: Pembrolizumab
- Procedur: Computed Tomography
- Procedur: Biopsy Procedure
- Procedur: Surgical Procedure
- Procedur: Magnetic Resonance Imaging
- Procedur: Positron Emission Tomography
- Strålning: Spatially-fractionated Radiation Therapy
- Strålning: Photon Stereotactic Body Radiation Therapy
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-post: mayocliniccancerstudies@mayo.edu
Studieorter
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Rekrytering
- Mayo Clinic in Rochester
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-post: mayocliniccancerstudies@mayo.edu
-
Huvudutredare:
- Daniel K. Ebner, MD, MPH
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Patients with histologically confirmed human papillomavirus (HPV)/p16-unrelated squamous cell carcinoma of the oral cavity and:
- Either locally advanced (T3-T4) non-metastatic disease, or
- Radiation-naïve locoregionally recurrent disease (prior radiation to a site outside of the treatment fields is permitted)
-
Age ≥ 18 years old
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
-
Eligible to receive immunotherapy on multidisciplinary evaluation
-
Ability to complete questionnaire(s) by themselves or with assistance
-
Provide signed written informed consent in accordance with ethical, regulatory, and institutional requirements
-
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
-
Willing to consent to and provide tissue and blood samples for correlative research purposes (not the optional Riskguard and OncoExtra testing)
-
PD-L1 combined positive score ≥ 1
Exclusion Criteria:
-
Participation in another clinical study with an investigational product during the last 3 months (12 weeks)
- Exception: Unless it is an observational (non-interventional) clinical study during the follow-up period of the study
-
Contraindications to pembrolizumab
-
Prior radiation therapy to the head and neck
-
Previous anticancer therapeutic received ≤ 30 days prior to registration, or adequate washout period on a per-agent basis, or concurrent anti-cancer therapeutic not specified by this protocol
-
Uncontrolled pre-existing condition(s), such as infection, congestive heart failure, hypertension, angina, arrhythmia, chronic diarrhea, psychiatric conditions, or others, that in the opinion of the treating investigator limits the ability to provide consent or longitudinal participation in this study
-
Inability to place 2 or more SFRT spheres within the tumor target
-
Prophylactic placement of feeding tubes is not allowed
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm A (proton SFRT, pembrolizumab, surgery)
Patients receive proton SFRT QOD for up to 3 treatment fractions over 1 week. Starting within 7 days of initiating SFRT, patients receive pembrolizumab IV on day 1 of each cycle. Cycles repeat every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Within 8 weeks of completing pembrolizumab, patients undergo surgical resection per standard of care. Patients also undergo blood sample collection, CT, and PET/MRI or PET/CT throughout the study. Additionally, patients may also undergo tissue biopsy at baseline and/or on study. |
Undergo blood sample collection
Andra namn:
Given IV
Andra namn:
Undergo CT or PET/CT
Andra namn:
Undergo tissue biopsy
Andra namn:
Undergo surgical resection
Andra namn:
Undergo PET/MRI
Andra namn:
Undergo PET/CT or PET/MRI
Andra namn:
Receive proton SFRT
Andra namn:
|
|
Experimentell: Arm B (photon SBRT, pembrolizumab, surgery)
Patients receive photon SBRT QOD for up to 3 treatment fractions over 1 week. Starting within 7 days of initiating SBRT, patients receive pembrolizumab IV on day 1 of each cycle. Cycles repeat every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Within 8 weeks of completing pembrolizumab, patients undergo surgical resection per standard of care. Patients also undergo blood sample collection, CT, and PET/MRI or PET/CT throughout the study. Additionally, patients may also undergo tissue biopsy at baseline and/or on study. |
Undergo blood sample collection
Andra namn:
Given IV
Andra namn:
Undergo CT or PET/CT
Andra namn:
Undergo tissue biopsy
Andra namn:
Undergo surgical resection
Andra namn:
Undergo PET/MRI
Andra namn:
Undergo PET/CT or PET/MRI
Andra namn:
Receive photon SBRT
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Improvement in major pathologic response rate (MPR)
Tidsram: At the time of surgical resection
|
MPR is defined from pathologic evaluation of the surgically resected tumor, demonstrating less than 10% of residual tumor in the resection sample (≥90% disease reduction). Will be assessed using a Bayesian pick-the-winner randomized phase-II clinical trial design. |
At the time of surgical resection
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pathologic complete response rate
Tidsram: At the time of surgical resection
|
Pathologic complete response rate is defined from pathologic evaluation of the surgically resected tumor, demonstrating no signs of residual disease following immuno-radiation. This will be calculated separately for Arm A and for Arm B. |
At the time of surgical resection
|
|
Percent of patients receiving the prescribed therapy
Tidsram: Up to 1 year
|
Will be defined as the number of patients who received the prescribed therapy divided by the number of evaluable patients who signed a consent form and began treatment. This will be calculated separately for Arm A and Arm B. |
Up to 1 year
|
|
Incidence of Adverse Events (AEs) Prior to Surgery:
Tidsram: From the time of registration until surgery
|
Overall AEs, overall toxicities, and by maximum grade per type of AE per patient of the AEs that occur before surgery will be explored and summarized descriptively, mainly through the use of frequency tables. Toxicity is defined as an adverse event that is classified as possibly, probably, or definitely related to study treatment. AEs are graded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. |
From the time of registration until surgery
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Daniel K. Ebner, MD, MPH, Mayo Clinic in Rochester
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Neoplasmer efter histologisk typ
- Neoplasmer i huvud och hals
- Neoplasmer, körtel och epitel
- Carcinom
- Karcinom, skivepitel
- Skivepitelcancer i huvud och hals
- Undersökningstekniker
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Cytologiska tekniker
- Cytodiagnos
- Diagnostiska tekniker, kirurgiska
- Kemitekniker, analytiska
- Spektrumanalys
- Biopsi
- Provhantering
- pembrolizumab
- Magnetresonansspektroskopi
- Kirurgiska ingrepp, operativ
Andra studie-ID-nummer
- GMROR2472
- NCI-2026-05918 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- 24-011038 (Annan identifierare: Mayo Clinic Institutional Review Board)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .